Latest Cambridge Antibody Technology Stories
LONDON, February 4 /PRNewswire/ -- A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers. The CTD would like to collaborate with scientists in all universities to develop drug...
NEW YORK, Dec.
NEW YORK, Nov.
ROCKVILLE, Md., Nov.
COPENHAGEN and OSLO, September 1 /PRNewswire-FirstCall/ -- Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that it has appointed two experienced biotech executives to head its management team. Dr Robert Burns, previously CEO of Celldex Therapeutics Inc., has today assumed overall responsibility for Affitech as its new Chief Executive Officer.
GAITHERSBURG, Md., Aug. 10 /PRNewswire/ -- MedImmune today announced that it has advanced three oncology antibody programs into Phase 1 clinical development within the past six months. All three of the antibody candidates will target a variety of advanced solid tumors, but via different pathways.
EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc.
SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire/ -- Catalyst Biosciences, Inc.
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease. Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a...
OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an antibody-coliphage pIII fusion protein, to identify tumor associated antigens on cells by negative selection.
- The word or words serving to define another word or expression, as in a dictionary entry.